Targeted Therapy with Dalpiciclib in a Pediatric Patient with Anaplastic Ependymoma: A Case Study and Literature Review
This report represents the first use of the CDK4/6 inhibitor Dalpiciclib for the treatment of anaplastic ependymoma. The treatment was guided by insights from next-generation sequencing (NGS) analysis and has shown promising results in terms of patient survival.
Authors
- Rongjie Tao
- Huaguo Wu
- Hui Zhang (ORCID: https://orcid.org/0000-0002-5761-0841)
- Li Yang (ORCID: https://orcid.org/0000-0002-7880-2113)
- Yue Qi (ORCID: https://orcid.org/0000-0001-7670-8599)
- Jia Yang (ORCID: https://orcid.org/0000-0001-5218-8218)
- Long Lai
Institutions
- Shandong Tumor Hospital (CN)
- Qilu Hospital of Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Recent Patents on Anti-Cancer Drug Discovery
- Published
- 2025-08-12
- DOI
- https://doi.org/10.2174/0115748928392108250728050114
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00